Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

Abstract Background Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recu...

Full description

Bibliographic Details
Main Authors: B. Frigerio, S. Morlino, E. Luison, E. Seregni, A. Lorenzoni, A. Satta, R. Valdagni, A. Bogni, C. Chiesa, M. Mira, S. Canevari, A. Alessi, M. Figini
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
PCa
124I
scFv
Antibody fragment
PET
Online Access:http://link.springer.com/article/10.1186/s13046-019-1325-6

Internet

http://link.springer.com/article/10.1186/s13046-019-1325-6

Similar Items